Issue #524 · Complete flagged-reference inventory
435 flagged records · 106 cited reference identifiers ·
19 TMB references · 87 response references ·
3 records without a direct citation.
61 references with snapshot PMCIDs ·
62 references with PMC document links.
Bibliographic snapshot acquired 2026-10-05T17:09:06.479070+00:00.
PubMed and the DOI registry establish citation identity and available document links.
Existing numeric locators retain their prior status; exact values, populations and denominators
still require scientific review.
Identifiers come from the frozen bibliographic snapshot. Links labeled
“Existing source document” come from prior source-locator records and retain their review status.
Reference CSV ·
All mapped records ·
Uncited records ·
Lookup and coverage audit
Recovered source chains and remaining gaps
SARC_CHOR: Review reference 42 points to Bai et al. 2021. Original study explicitly reports median 0.53 mutations/Mb in 80 distinct skull-base chordoma tumors. The broader registry population and WGS definition remain to be reviewed. NPC: The downloaded article body does not contain the exact retained 0.95 value. Its TMB discussion does not establish the curated median; an original source for that exact estimate remains unresolved. 22 TMB records: NIHMS471461-supplement-1.pdf; NIHMS471461-supplement-2.txt; NIHMS471461-supplement-3.xls. These are supplement pointers, not validation of the 22 curated per-cancer medians. ICI-dfd5824394-01: The row is a prevalence-weighted modeled blend. These papers support component cohorts rather than a single observed all-comer rate. The prevalence weights in the row notes still have no explicit source citation. ICI-f37d406872-01: The row is a prevalence-weighted modeled blend. These papers support component cohorts rather than a single observed all-comer rate. The prevalence weights in the row notes still have no explicit source citation. ICI-506b32f2a7-01: The row is a prevalence-weighted modeled blend. These papers support component cohorts rather than a single observed all-comer rate. The prevalence weights in the row notes still have no explicit source citation. Source-chain mapping ·
Recovered original chordoma reference
All references
TMB Response
R019 · Mutational heterogeneity in cancer and the search for new cancer-associated genes. PMID:23770567 · Nature · 2013 · 22 flagged records
Identifiers (bibliographic snapshot): PMID:23770567 · DOI:10.1038/nature12213 · PMCID:PMC3919509
Citation · Publisher / DOI · PMC full text
Cancer codes: BLCA; BRCA; CESC; CLL; COAD; DLBC; ESCA; GBM; HNSC; KIRC; LAML; LGG; LUAD; LUSC; MBL; MM; OV; PRAD; READ; RT; SKCM; UCEC
Flags: tmb_source_not_revalidated
Source trace: NIHMS471461-supplement-1.pdf; NIHMS471461-supplement-2.txt; NIHMS471461-supplement-3.xls. These are supplement pointers, not validation of the 22 curated per-cancer medians.
Show 22 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb BLCA BLCA TMB 7.1 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb BRCA BRCA TMB 1.2 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb CESC CESC TMB 5.0 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb COAD COAD TMB 3.1 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb DLBC DLBC TMB 3.3 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb ESCA ESCA TMB 4.0 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb GBM GBM TMB 2.2 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb HNSC HNSC TMB 3.9 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb KIRC KIRC TMB 1.9 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb LAML LAML TMB 0.4 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb LGG LGG TMB 1.0 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb LUAD LUAD TMB 8.1 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb LUSC LUSC TMB 9.9 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb OV OV TMB 1.7 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb PRAD PRAD TMB 0.7 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb READ READ TMB 3.1 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb SKCM SKCM TMB 12.9 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb UCEC UCEC TMB 2.5 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb RT RT TMB 0.1 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb MBL MBL TMB 0.3 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb MM MM TMB 1.6 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians cancer-tmb CLL CLL TMB 0.6 sample_size_not_curated;tmb_source_not_revalidated Figure 1; supplementary per-sample data needed for exact subgroup medians
R043 · The landscape of genomic alterations across childhood cancers. PMID:29489754 · Nature · 2018 · 12 flagged records
Identifiers (bibliographic snapshot): PMID:29489754 · DOI:10.1038/nature25480
Citation · Publisher / DOI
Cancer codes: ATRT; B_ALL; EPN; HEPB; SARC_EWS; SARC_OS; SARC_RMS_ARMS; SARC_RMS_ERMS; SARC_RMS_PRMS; SARC_RMS_SSRMS; T_ALL; WILMS
Flags: tmb_source_not_revalidated
Show 12 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb SARC_OS SARC_OS TMB 1.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_EWS SARC_EWS TMB 0.6 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_RMS_ERMS SARC_RMS_ERMS TMB 0.8 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated;tmb_statistic_or_derivation_requires_review cancer-tmb SARC_RMS_ARMS SARC_RMS_ARMS TMB 0.4 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated;tmb_statistic_or_derivation_requires_review cancer-tmb WILMS WILMS TMB 0.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated;tmb_statistic_or_derivation_requires_review cancer-tmb ATRT ATRT TMB 0.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb HEPB HEPB TMB 0.02 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb B_ALL B_ALL TMB 0.3 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb T_ALL T_ALL TMB 0.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated;tmb_statistic_or_derivation_requires_review cancer-tmb SARC_RMS_PRMS SARC_RMS_PRMS TMB 1.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_RMS_SSRMS SARC_RMS_SSRMS TMB 0.6 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb EPN EPN TMB 0.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R003 · Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. DOI:10.1016/j.cell.2017.10.014 · Cell · 2017 · 7 flagged records
Identifiers (bibliographic snapshot): PMID:29100075 · DOI:10.1016/j.cell.2017.10.014 · PMCID:PMC5693358
Citation · PMC full text
Cancer codes: SARC; SARC_DDLPS; SARC_LMS; SARC_LPS_UNSPEC; SARC_MYXFIB; SARC_SYN; SARC_UPS
Flags: tmb_source_not_revalidated
Show 7 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb SARC_LMS SARC_LMS TMB 2.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_DDLPS SARC_DDLPS TMB 1.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_UPS SARC_UPS TMB 2.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_MYXFIB SARC_MYXFIB TMB 2.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_SYN SARC_SYN TMB 1.7 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC SARC TMB 1.8 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb SARC_LPS_UNSPEC SARC_LPS_UNSPEC TMB 1.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R017 · Comprehensive molecular portraits of human breast tumours. PMID:23000897 · Nature · 2012 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:23000897 · DOI:10.1038/nature11412 · PMCID:PMC3465532
Citation · Publisher / DOI · PMC full text
Cancer codes: BRCA_Basal; BRCA_HER2; BRCA_LumA; BRCA_LumB
Flags: tmb_source_not_revalidated
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb BRCA_Basal BRCA_Basal TMB 1.8 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb BRCA_HER2 BRCA_HER2 TMB 1.6 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb BRCA_LumB BRCA_LumB TMB 1.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb BRCA_LumA BRCA_LumA TMB 0.9 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R034 · Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. PMID:28420421 · Genome medicine · 2017 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:28420421 · DOI:10.1186/s13073-017-0424-2 · PMCID:PMC5395719
Citation · Publisher / DOI · PMC full text
Cancer codes: CRC_MSI; KICH; PCPG; TGCT
Flags: tmb_source_not_revalidated
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb KICH KICH TMB 0.7 sample_size_not_curated;tmb_source_not_revalidated Figure 2 / Additional file 3, Table S1; exact row not revalidated cancer-tmb PCPG PCPG TMB 0.5 sample_size_not_curated;tmb_source_not_revalidated Figure 2 / Additional file 3, Table S1; exact row not revalidated cancer-tmb TGCT TGCT TMB 0.5 sample_size_not_curated;tmb_source_not_revalidated Figure 2 / Additional file 3, Table S1; exact row not revalidated cancer-tmb CRC_MSI CRC_MSI TMB 46 sample_size_not_curated;tmb_source_not_revalidated Figure 2 / Additional file 3, Table S1; exact row not revalidated
R035 · The whole-genome landscape of medulloblastoma subtypes. PMID:28726821 · Nature · 2017 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:28726821 · DOI:10.1038/nature22973 · PMCID:PMC5905700
Citation · Publisher / DOI · PMC full text
Cancer codes: MBL_G3; MBL_G4; MBL_SHH; MBL_WNT
Flags: tmb_source_not_revalidated
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb MBL_WNT MBL_WNT TMB 0.6 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb MBL_SHH MBL_SHH TMB 0.8 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb MBL_G3 MBL_G3 TMB 0.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb MBL_G4 MBL_G4 TMB 0.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R021 · Comprehensive genomic characterization of head and neck squamous cell carcinomas. PMID:25631445 · Nature · 2015 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:25631445 · DOI:10.1038/nature14129 · PMCID:PMC4311405
Citation · Publisher / DOI · PMC full text
Cancer codes: HNSC_HPVneg; HNSC_HPVpos
Flags: tmb_source_not_revalidated
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb HNSC_HPVneg HNSC_HPVneg TMB 4.6 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated cancer-tmb HNSC_HPVpos HNSC_HPVpos TMB 2.8 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R004 · The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. DOI:10.1016/j.celrep.2024.113826 · Cell reports · 2024 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:38412093 · DOI:10.1016/j.celrep.2024.113826 · PMCID:PMC11077417
Citation · PMC full text
Cancer codes: ATC
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb ATC ATC TMB 3.8 assay_not_structured;tmb_source_not_revalidated
R007 · An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. DOI:10.1038/s41598-018-31659-0 · Scientific reports · 2018 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:30202034 · DOI:10.1038/s41598-018-31659-0 · PMCID:PMC6131140
Citation · PMC full text
Cancer codes: MENINGIOMA
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb MENINGIOMA MENINGIOMA TMB 0.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R018 · The genetic landscape of mutations in Burkitt lymphoma. PMID:23143597 · Nature genetics · 2012 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:23143597 · DOI:10.1038/ng.2468 · PMCID:PMC3674561
Citation · Publisher / DOI · PMC full text
Cancer codes: BL
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb BL BL TMB 2.0 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated;tmb_statistic_or_derivation_requires_review
R020 · Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. PMID:24413733 · Nature genetics · 2014 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:24413733 · DOI:10.1038/ng.2868 · PMCID:PMC3982316
Citation · Publisher / DOI · PMC full text
Cancer codes: CRANIO
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb CRANIO CRANIO TMB 0.9 tmb_source_not_revalidated Main text preceding Figure 1; Figure 1 legend; Supplementary Tables 1-2; https://pmc.ncbi.nlm.nih.gov/articles/PMC3982316/
R025 · Comprehensive genomic profiles of small cell lung cancer. PMID:26168399 · Nature · 2015 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:26168399 · DOI:10.1038/nature14664 · PMCID:PMC4861069
Citation · Publisher / DOI · PMC full text
Cancer codes: SCLC
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb SCLC SCLC TMB 8.6 tmb_source_not_revalidated;tmb_statistic_or_derivation_requires_review Results: Recurrent somatic alterations in SCLC; Supplementary Tables 1-3; https://pmc.ncbi.nlm.nih.gov/articles/PMC4861069/
R038 · Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. PMID:28966033 · Cancer cell · 2017 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:28966033 · DOI:10.1016/j.ccell.2017.08.017 · PMCID:PMC5637314
Citation · Publisher / DOI · PMC full text
Cancer codes: DIPG
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb DIPG DIPG TMB 1.0 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R050 · Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis. PMID:29901569 · The American journal of surgical pathology · 2018 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:29901569 · DOI:10.1097/PAS.0000000000001098
Citation · Publisher / DOI
Cancer codes: SARC_CIC
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb SARC_CIC SARC_CIC TMB 1.2 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R052 · Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. PMID:30151257 · Journal of gastrointestinal oncology · 2018 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:30151257 · DOI:10.21037/jgo.2018.05.06 · PMCID:PMC6087857
Citation · Publisher / DOI · PMC full text
Cancer codes: CRC
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb CRC CRC TMB 4.5 assay_not_structured;tmb_source_not_revalidated
R064 · The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. PMID:31399473 · Clinical cancer research : an official journal of the American Association for Cancer Research · 2019 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:31399473 · DOI:10.1158/1078-0432.CCR-18-4159 · PMCID:PMC6774882
Citation · Publisher / DOI · PMC full text
Cancer codes: NEC_MERKEL
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb NEC_MERKEL NEC_MERKEL TMB 5.3 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R077 · The genetic landscape of choroid plexus tumors in children and adults. PMID:33249490 · Neuro-oncology · 2021 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33249490 · DOI:10.1093/neuonc/noaa267 · PMCID:PMC8041331
Citation · Publisher / DOI · PMC full text
Cancer codes: CHOROID_PLEXUS
Flags: tmb_source_not_revalidated
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb CHOROID_PLEXUS CHOROID_PLEXUS TMB 0.5 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R095 · Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection. PMID:36135044 · Current oncology (Toronto, Ont.) · 2022 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:36135044 · DOI:10.3390/curroncol29090475 · PMCID:PMC9498130
Citation · Publisher / DOI · PMC full text
Cancer codes: NPC
Flags: tmb_source_not_revalidated
Source trace: The downloaded article body does not contain the exact retained 0.95 value. Its TMB discussion does not establish the curated median; an original source for that exact estimate remains unresolved.
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb NPC NPC TMB 0.95 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R101 · Chordoma: Genetics and Contemporary Management. PMID:38892063 · International journal of molecular sciences · 2024 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:38892063 · DOI:10.3390/ijms25115877 · PMCID:PMC11172617
Citation · Publisher / DOI · PMC full text · Traced source
Cancer codes: SARC_CHOR
Flags: tmb_source_not_revalidated
Source trace: Review reference 42 points to Bai et al. 2021. Original study explicitly reports median 0.53 mutations/Mb in 80 distinct skull-base chordoma tumors. The broader registry population and WGS definition remain to be reviewed.
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-tmb SARC_CHOR SARC_CHOR TMB 0.53 assay_not_structured;sample_size_not_curated;tmb_source_not_revalidated
R098 · Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. PMID:37429302 · The Lancet. Oncology · 2023 · 21 flagged records
Identifiers (bibliographic snapshot): PMID:37429302 · DOI:10.1016/S1470-2045(23)00282-6
Citation · Publisher / DOI
Cancer codes: SARC_CHOR; SARC_DSRCT; SARC_EPITH; SARC_SMARCA4
Flags: numeric_source_location_not_verified; response_denominator_missing; small_denominator
Show 21 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SARC_DSRCT/PD-1 SARC_DSRCT ORR 12.5 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response SARC_EPITH/PD-1 SARC_EPITH ORR 16.7 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response SARC_SMARCA4/PD-1 SARC_SMARCA4 ORR 25.0 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response SARC_SMARCA4/PD-1 SARC_SMARCA4 ORR 25.0 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response SARC_EPITH/PD-1 SARC_EPITH ORR 16.7 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-apd1-response SARC_DSRCT/PD-1 SARC_DSRCT ORR 12.5 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response-estimates ICI-9d9b2a4f31-01 SARC_CHOR CRR 0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-0643a1207d-01 SARC_CHOR DCR 83 numeric_source_location_not_verified;response_denominator_missing Abstract, Findings cancer-ici-response-estimates ICI-c22314cfc5-01 SARC_CHOR PFS 6.6 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-a95ee422da-01 SARC_CHOR PFS_RATE 31.2 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-20f6937be0-01 SARC_CHOR OS_RATE 76.6 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-a44c21bbe4-01 SARC_CHOR ORR 6.2 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-07b7aa4086-01 SARC_CHOR PFS 2.8 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-55894ec561-01 SARC_CHOR OS 19.7 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-c21f2242ff-01 SARC_DSRCT ORR 12.5 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response-estimates ICI-def38304ee-01 SARC_DSRCT CRR 0 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response-estimates ICI-a2e719caec-01 SARC_EPITH ORR 16.7 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response-estimates ICI-ede3c1f501-01 SARC_SMARCA4 ORR 25 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-e2003093ee-01 SARC_SMARCA4 DCR 50 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-458b806694-01 SARC_SMARCA4 DOR 13.3 numeric_source_location_not_verified;small_denominator Abstract, Findings cancer-ici-response-estimates ICI-2e46a4627a-01 SARC_SMARCA4 PFS 2 numeric_source_location_not_verified Abstract, Findings
R013 · Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. DOI:10.1200/JCO.2019.37.15_suppl.11015 · Journal of Clinical Oncology · 2019 · 18 flagged records
Identifiers (bibliographic snapshot): DOI:10.1200/jco.2019.37.15_suppl.11015
Citation · Publisher / DOI
Cancer codes: SARC_DDLPS; SARC_UPS
Flags: numeric_source_location_not_verified
Show 18 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SARC_DDLPS/PD-1 SARC_DDLPS ORR 10 numeric_source_location_not_verified cancer-ici-response SARC_UPS/PD-1 SARC_UPS ORR 23 numeric_source_location_not_verified cancer-apd1-response SARC_UPS/PD-1 SARC_UPS ORR 23 numeric_source_location_not_verified cancer-apd1-response SARC_DDLPS/PD-1 SARC_DDLPS ORR 10 numeric_source_location_not_verified cancer-ici-response-estimates ICI-8a975a40d8-01 SARC_DDLPS ORR 10 numeric_source_location_not_verified cancer-ici-response-estimates ICI-9a6eed08d9-01 SARC_DDLPS CRR 0 numeric_source_location_not_verified cancer-ici-response-estimates ICI-8a35e54935-01 SARC_DDLPS PFS 2 numeric_source_location_not_verified cancer-ici-response-estimates ICI-57d61767e6-01 SARC_DDLPS PFS_RATE 44 numeric_source_location_not_verified cancer-ici-response-estimates ICI-6c88fa7795-01 SARC_DDLPS OS 13 numeric_source_location_not_verified cancer-ici-response-estimates ICI-27d906d8d8-01 SARC_UPS ORR 23 numeric_source_location_not_verified cancer-ici-response-estimates ICI-56ba2f840b-01 SARC_UPS CRR 5 numeric_source_location_not_verified cancer-ici-response-estimates ICI-5a30bd2006-01 SARC_UPS PFS 3 numeric_source_location_not_verified cancer-ici-response-estimates ICI-72b03ee23c-01 SARC_UPS PFS_RATE 50 numeric_source_location_not_verified cancer-ici-response-estimates ICI-6b8787485e-01 SARC_UPS OS 12 numeric_source_location_not_verified cancer-ici-response-estimates ICI-dcdc418d17-01 SARC_UPS ORR 10 excluded_from_pooling;numeric_source_location_not_verified cancer-ici-response-estimates ICI-f646ad58df-01 SARC_UPS PFS 2 numeric_source_location_not_verified cancer-ici-response-estimates ICI-1793125d04-01 SARC_UPS PFS_RATE 44 numeric_source_location_not_verified cancer-ici-response-estimates ICI-40e61d0514-01 SARC_UPS OS 13 numeric_source_location_not_verified
R008 · Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma DOI:10.1056/EVIDoa2100070 · NEJM Evidence · 2022 · 15 flagged records
Identifiers (bibliographic snapshot): DOI:10.1056/evidoa2100070
Citation
Cancer codes: LIHC
Flags: numeric_source_location_not_verified
Show 15 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response LIHC/PD-L1 LIHC ORR 17.0 numeric_source_location_not_verified cancer-ici-response-estimates ICI-e29b6e85a5-01 LIHC ORR 17 numeric_source_location_not_verified cancer-ici-response-estimates ICI-3356419757-01 LIHC CRR 1.5 numeric_source_location_not_verified cancer-ici-response-estimates ICI-212d27db9c-01 LIHC OS 16.6 numeric_source_location_not_verified cancer-ici-response-estimates ICI-15e3b58699-01 LIHC OS_RATE 24.7 numeric_source_location_not_verified cancer-ici-response-estimates ICI-83bfc48f29-01 LIHC ORR 20.1 numeric_source_location_not_verified cancer-ici-response-estimates ICI-608df4bed5-01 LIHC CRR 3.1 numeric_source_location_not_verified cancer-ici-response-estimates ICI-ad825ad73b-01 LIHC PFS 3.78 numeric_source_location_not_verified cancer-ici-response-estimates ICI-ef9705b258-01 LIHC OS 16.43 numeric_source_location_not_verified cancer-ici-response-estimates ICI-50158d5c35-01 LIHC OS_RATE 30.7 numeric_source_location_not_verified cancer-ici-response-estimates ICI-243fff63b6-01 LIHC ORR 5.1 excluded_from_pooling;numeric_source_location_not_verified cancer-ici-response-estimates ICI-f834cd0444-01 LIHC CRR 0 excluded_from_pooling;numeric_source_location_not_verified cancer-ici-response-estimates ICI-17b105bce4-01 LIHC PFS 4.07 numeric_source_location_not_verified cancer-ici-response-estimates ICI-35b9cfa565-01 LIHC OS 13.77 numeric_source_location_not_verified cancer-ici-response-estimates ICI-1a577b99d3-01 LIHC OS_RATE 20.2 numeric_source_location_not_verified
R028 · Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. PMID:27269741 · The Lancet. Oncology · 2016 · 14 flagged records
Identifiers (bibliographic snapshot): PMID:27269741 · DOI:10.1016/S1470-2045(16)30098-5
Citation · Publisher / DOI
Cancer codes: SCLC
Flags: numeric_source_location_not_verified
Show 14 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SCLC/PD-1 SCLC ORR 10.0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response SCLC/PD-1+CTLA-4 SCLC ORR 23.0 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response SCLC/PD-1 SCLC ORR 10.0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-367f3b5460-01 SCLC ORR 10 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-82493d756c-01 SCLC PFS 1.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-41ab79b829-01 SCLC OS 4.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-e5955363a7-01 SCLC ORR 23 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-49a3e7662d-01 SCLC ORR 19 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-f5a30654c5-01 SCLC ORR 23 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-95006a6a56-01 SCLC ORR 10 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-f88742e370-01 SCLC ORR 19 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-23cadc3e71-01 SCLC ORR 23 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-42926cc658-01 SCLC DOR 11.7 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-29c468a953-01 SCLC OS_RATE 43 numeric_source_location_not_verified Abstract, Findings
R039 · Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. PMID:28988646 · The Lancet. Oncology · 2017 · 12 flagged records
Identifiers (bibliographic snapshot): PMID:28988646 · DOI:10.1016/S1470-2045(17)30624-1 · PMCID:PMC7939029
Citation · Publisher / DOI · PMC full text
Cancer codes: SARC_CHON; SARC_DDLPS; SARC_EWS; SARC_LMS; SARC_OS; SARC_SYN
Flags: numeric_source_location_not_verified; small_denominator
Show 12 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SARC_CHON/PD-1 SARC_CHON ORR 20 small_denominator RESULTS cancer-ici-response SARC_SYN/PD-1 SARC_SYN ORR 10.0 numeric_source_location_not_verified Abstract, Findings: cancer-apd1-response SARC_SYN/PD-1 SARC_SYN ORR 10.0 numeric_source_location_not_verified Abstract, Findings: cancer-apd1-response SARC_CHON/PD-1 SARC_CHON ORR 20 small_denominator RESULTS cancer-ici-response-estimates ICI-c813ebc19a-01 SARC_CHON ORR 20 small_denominator RESULTS cancer-ici-response-estimates ICI-9e0fec3287-01 SARC_CHON CRR 0 numeric_source_location_not_verified;small_denominator Abstract, Findings: cancer-ici-response-estimates ICI-c2623b060c-01 SARC_DDLPS CRR 2.5 excluded_from_pooling;numeric_source_location_not_verified Abstract, Findings: cancer-ici-response-estimates ICI-39a714d8c2-01 SARC_DDLPS DOR 33 small_denominator RESULTS cancer-ici-response-estimates ICI-ab0d19608c-01 SARC_EWS ORR 20 small_denominator RESULTS cancer-ici-response-estimates ICI-5def647922-01 SARC_LMS ORR 10 excluded_from_pooling;numeric_source_location_not_verified Abstract, Findings: cancer-ici-response-estimates ICI-7e796043d1-01 SARC_OS ORR 20 small_denominator RESULTS cancer-ici-response-estimates ICI-a166d88a43-01 SARC_SYN ORR 10 numeric_source_location_not_verified Abstract, Findings:
R044 · Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. PMID:29543932 · JAMA oncology · 2018 · 10 flagged records
Identifiers (bibliographic snapshot): PMID:29543932 · DOI:10.1001/jamaoncol.2018.0013 · PMCID:PMC5885175
Citation · Publisher / DOI · PMC full text
Cancer codes: STAD; STAD_MSI
Flags: numeric_source_location_not_verified; small_denominator
Show 10 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response STAD_MSI/PD-1 STAD_MSI ORR 57.1 small_denominator Results, Microsatellite Instability cancer-apd1-response STAD_MSI/PD-1 STAD_MSI ORR 57.1 small_denominator Results, Microsatellite Instability cancer-ici-response-estimates ICI-57fb7038b4-01 STAD DOR 8.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-a0389e6e5e-01 STAD PFS 2 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-cab740b982-01 STAD OS 5.6 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-09663178bb-01 STAD OS_RATE 46.5 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-ccaccda0f7-01 STAD OS_RATE 23.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-33cc121b26-01 STAD DOR 16.3 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-cf87d987e7-01 STAD DOR 6.9 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-2a7de231fa-01 STAD_MSI ORR 57.1 small_denominator Results, Microsatellite Instability
R059 · Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. PMID:30620669 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · 9 flagged records
Identifiers (bibliographic snapshot): PMID:30620669 · DOI:10.1200/JCO.18.00766 · PMCID:PMC6528729
Citation · Publisher / DOI · PMC full text
Cancer codes: DLBC
Flags: numeric_source_location_not_verified
Show 9 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-fad62b3255-01 DLBC CRR 3 numeric_source_location_not_verified cancer-ici-response-estimates ICI-b8f9719958-01 DLBC DOR 11 numeric_source_location_not_verified cancer-ici-response-estimates ICI-4182f54785-01 DLBC PFS 1.9 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-1978c8ccd2-01 DLBC OS 12.2 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-5ccaa6b719-01 DLBC ORR 3 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-c8e2ba8f45-01 DLBC CRR 0 numeric_source_location_not_verified cancer-ici-response-estimates ICI-aef2b3301d-01 DLBC DOR 8.3 numeric_source_location_not_verified cancer-ici-response-estimates ICI-732c723e34-01 DLBC PFS 1.4 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-1452386811-01 DLBC OS 5.8 numeric_source_location_not_verified Abstract, Results
R080 · First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. PMID:33485464 · Lancet (London, England) · 2021 · 9 flagged records
Identifiers (bibliographic snapshot): PMID:33485464 · DOI:10.1016/S0140-6736(20)32714-8
Citation · Publisher / DOI
Cancer codes: MESO
Flags: numeric_source_location_not_verified
Show 9 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response MESO/PD-1+CTLA-4 MESO ORR 40.0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-436bf42bcc-01 MESO ORR 40 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-b076397f08-01 MESO PFS 6.8 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-3eedef77bf-01 MESO DOR 11 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-fc34e216db-01 MESO ORR 43 excluded_from_pooling;numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-ec1c116e7f-01 MESO PFS 7.2 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-d8b4271412-01 MESO DOR 6.7 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-a2b8ab3474-01 MESO OS_RATE 23 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-334657565c-01 MESO DOR 11.6 numeric_source_location_not_verified Abstract, Findings
R001 · Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. DOI:10.1002/cncr.34657 · Cancer · 2023 · 8 flagged records
Identifiers (bibliographic snapshot): PMID:36748723 · DOI:10.1002/cncr.34657
Citation
Cancer codes: THCA
Flags: numeric_source_location_not_verified; small_denominator
Show 8 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response THCA/PD-1 THCA ORR 6.8 numeric_source_location_not_verified cancer-apd1-response THCA/PD-1 THCA ORR 6.8 numeric_source_location_not_verified cancer-ici-response-estimates ICI-b738c2d9c3-01 THCA ORR 6.8 numeric_source_location_not_verified cancer-ici-response-estimates ICI-b9da0f2f10-01 THCA DOR 18.4 numeric_source_location_not_verified;small_denominator cancer-ici-response-estimates ICI-c9e54f1c59-01 THCA PFS 4.2 numeric_source_location_not_verified cancer-ici-response-estimates ICI-6c8a074707-01 THCA OS 34.5 numeric_source_location_not_verified cancer-ici-response-estimates ICI-3fda461db1-01 THCA ORR 8.7 numeric_source_location_not_verified cancer-ici-response-estimates ICI-3c091423d1-01 THCA ORR 5.7 numeric_source_location_not_verified
R005 · Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. DOI:10.1016/j.ejca.2018.11.015 · European journal of cancer (Oxford, England : 1990) · 2019 · 8 flagged records
Identifiers (bibliographic snapshot): PMID:30576970 · DOI:10.1016/j.ejca.2018.11.015
Citation
Cancer codes: HNSC
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 8 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response HNSC/PD-L1 HNSC ORR 16.2 numeric_source_location_not_verified cancer-ici-response-estimates ICI-115459b2ac-01 HNSC ORR 16.2 numeric_source_location_not_verified cancer-ici-response-estimates ICI-1c58e794bd-01 HNSC PFS 2.1 numeric_source_location_not_verified cancer-ici-response-estimates ICI-0806626c27-01 HNSC OS 7.1 numeric_source_location_not_verified cancer-ici-response-estimates ICI-68b73b8a7c-01 HNSC OS_RATE 33.6 numeric_source_location_not_verified cancer-ici-response-estimates ICI-63197a5a9a-01 HNSC PFS_RATE 14.6 numeric_source_location_not_verified cancer-ici-response-estimates ICI-33e04a560a-01 HNSC ORR 29.4 numeric_source_location_not_verified;response_denominator_missing cancer-ici-response-estimates ICI-399cb5d0cb-01 HNSC ORR 10.9 numeric_source_location_not_verified;response_denominator_missing
R069 · Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. PMID:31679945 · Lancet (London, England) · 2019 · 8 flagged records
Identifiers (bibliographic snapshot): PMID:31679945 · DOI:10.1016/S0140-6736(19)32591-7
Citation · Publisher / DOI
Cancer codes: HNSC
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 8 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response HNSC/PD-1 HNSC ORR 19.0 numeric_source_location_not_verified;response_denominator_missing Abstract, Findings cancer-apd1-response HNSC/PD-1 HNSC ORR 19.0 numeric_source_location_not_verified;response_denominator_missing Abstract, Findings cancer-ici-response-estimates ICI-61867d5430-01 HNSC ORR 19 numeric_source_location_not_verified;response_denominator_missing Abstract, Findings cancer-ici-response-estimates ICI-3d65890d97-01 HNSC DOR 23.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-3db57f96fc-01 HNSC ORR 17 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-4c8dcac8de-01 HNSC DOR 22.6 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-743e9b1529-01 HNSC ORR 23 numeric_source_location_not_verified;response_denominator_missing Abstract, Findings cancer-ici-response-estimates ICI-6d0e8d650e-01 HNSC DOR 22.6 numeric_source_location_not_verified Abstract, Findings
R082 · Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. PMID:33836153 · The Lancet. Respiratory medicine · 2021 · 8 flagged records
Identifiers (bibliographic snapshot): PMID:33836153 · DOI:10.1016/S2213-2600(20)30515-4
Citation · Publisher / DOI
Cancer codes: MESO
Flags: numeric_source_location_not_verified
Show 8 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response MESO/PD-1 MESO ORR 8.5 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response MESO/PD-1 MESO ORR 8.5 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-96dcba4ace-01 MESO ORR 8.5 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-789050bded-01 MESO CRR 0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-94c74816c2-01 MESO DOR 14.3 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-17009f0210-01 MESO PFS_RATE 27 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-2ba924d213-01 MESO PFS_RATE 11 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-b69c9f3b38-01 MESO OS_RATE 45 numeric_source_location_not_verified Abstract, Findings
R036 · Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. PMID:28837405 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017 · 7 flagged records
Identifiers (bibliographic snapshot): PMID:28837405 · DOI:10.1200/JCO.2017.73.3675
Citation · Publisher / DOI
Cancer codes: NPC
Flags: numeric_source_location_not_verified; small_denominator
Show 7 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-e2e0c7bc2d-01 NPC CRR 0 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-49f4b7f6b3-01 NPC DCR 77.8 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-afbed127c7-01 NPC PFS 5.6 numeric_source_location_not_verified cancer-ici-response-estimates ICI-d5996912bf-01 NPC PFS_RATE 49.7 numeric_source_location_not_verified cancer-ici-response-estimates ICI-83f29e3c08-01 NPC PFS_RATE 30.1 numeric_source_location_not_verified cancer-ici-response-estimates ICI-c9c49d3d02-01 NPC OS_RATE 66.7 numeric_source_location_not_verified cancer-ici-response-estimates ICI-2c3303896a-01 NPC DOR small_denominator
R105 · Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results. PMID:39847999 · Gynecologic oncology · 2025 · 7 flagged records
Identifiers (bibliographic snapshot): PMID:39847999 · DOI:10.1016/j.ygyno.2024.12.020
Citation · Publisher / DOI
Cancer codes: UCEC_CNH; UCEC_CNL; UCEC_MSI
Flags: numeric_source_location_not_verified
Show 7 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response UCEC_MSI/PD-1 UCEC_MSI ORR 48 numeric_source_location_not_verified Abstract, Results cancer-apd1-response UCEC_MSI/PD-1 UCEC_MSI ORR 48 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-81454d98c0-01 UCEC_CNH CRR 0 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-bd96872001-01 UCEC_CNL CRR 0 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-71a3411cc4-01 UCEC_CNL MEDIAN_FOLLOW_UP 68.3 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-e3b25a0916-01 UCEC_MSI ORR 48.0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-dc53353bd1-01 UCEC_MSI MEDIAN_FOLLOW_UP 54.5 numeric_source_location_not_verified Abstract, Results
R106 · Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial. PMID:41760889 · NPJ precision oncology · 2026 · 7 flagged records
Identifiers (bibliographic snapshot): PMID:41760889 · DOI:10.1038/s41698-026-01303-6 · PMCID:PMC13065800
Citation · Publisher / DOI · PMC full text
Cancer codes: SARC_MPNST
Flags: numeric_source_location_not_verified; small_denominator
Show 7 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SARC_MPNST/PD-1 SARC_MPNST ORR 12.5 numeric_source_location_not_verified;small_denominator Abstract cancer-apd1-response SARC_MPNST/PD-1 SARC_MPNST ORR 12.5 numeric_source_location_not_verified;small_denominator Abstract cancer-ici-response-estimates ICI-3d5c73d0ec-01 SARC_MPNST ORR 12.5 numeric_source_location_not_verified;small_denominator Abstract cancer-ici-response-estimates ICI-3bdccb427b-01 SARC_MPNST CBR 12.5 numeric_source_location_not_verified;small_denominator Abstract cancer-ici-response-estimates ICI-702c35cb4f-01 SARC_MPNST DCR 62.5 numeric_source_location_not_verified;small_denominator Abstract cancer-ici-response-estimates ICI-02efacfe24-01 SARC_MPNST PFS 3.9 numeric_source_location_not_verified;small_denominator Abstract cancer-ici-response-estimates ICI-966f14ec2d-01 SARC_MPNST OS 7.3 numeric_source_location_not_verified;small_denominator Abstract
R022 · Pembrolizumab versus Ipilimumab in Advanced Melanoma. PMID:25891173 · The New England journal of medicine · 2015 · 6 flagged records
Identifiers (bibliographic snapshot): PMID:25891173 · DOI:10.1056/NEJMoa1503093
Citation · Publisher / DOI
Cancer codes: SKCM
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 6 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-f5d6afe3dc-01 SKCM ORR 33.7 numeric_source_location_not_verified;response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-53f27342de-01 SKCM PFS_RATE 47.3 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-396667cde6-01 SKCM OS_RATE 74.1 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-61af6d64ce-01 SKCM ORR 32.9 numeric_source_location_not_verified;response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-13894b2b45-01 SKCM PFS_RATE 46.4 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-217504b01d-01 SKCM OS_RATE 68.4 numeric_source_location_not_verified Abstract, Results
R063 · Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. PMID:31046082 · Annals of oncology : official journal of the European Society for Medical Oncology · 2019 · 6 flagged records
Identifiers (bibliographic snapshot): PMID:31046082 · DOI:10.1093/annonc/mdz135
Citation · Publisher / DOI
Cancer codes: OV
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 6 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response OV/PD-1 OV ORR 8.0 numeric_source_location_not_verified Abstract, Results cancer-apd1-response OV/PD-1 OV ORR 8.0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-d9b891ea7b-01 OV ORR 8 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-c42fbc7316-01 OV ORR 4.1 response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-24dc92c1d2-01 OV ORR 5.7 response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-ff2a7114e3-01 OV ORR 10 numeric_source_location_not_verified;response_denominator_missing Abstract, Results
R067 · Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. PMID:31582355 · The Lancet. Oncology · 2019 · 6 flagged records
Identifiers (bibliographic snapshot): PMID:31582355 · DOI:10.1016/S1470-2045(19)30626-6
Citation · Publisher / DOI
Cancer codes: ESCA
Flags: numeric_source_location_not_verified
Show 6 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response ESCA/PD-1 ESCA ORR 19.3 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response ESCA/PD-1 ESCA ORR 19.3 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-96b4d412b9-01 ESCA ORR 19.3 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-f81f4324e3-01 ESCA DOR 6.9 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-db97f9fefe-01 ESCA ORR 21.5 excluded_from_pooling;numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-a89af1a5e9-01 ESCA DOR 3.9 numeric_source_location_not_verified Abstract, Findings
R068 · Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. PMID:31639039 · Journal for immunotherapy of cancer · 2019 · 6 flagged records
Identifiers (bibliographic snapshot): PMID:31639039 · DOI:10.1186/s40425-019-0723-9 · PMCID:PMC6805423
Citation · Publisher / DOI · PMC full text
Cancer codes: THYM
Flags: numeric_source_location_not_verified; small_denominator
Show 6 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response THYM/PD-L1 THYM ORR 29.0 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-290c164100-01 THYM ORR 29 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-e531355aa2-01 THYM CRR 0 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-244928197d-01 THYM DCR 85.7 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-727d3fda5e-01 THYM UNCONFIRMED_ORR 57 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-642dd49c90-01 THYM ORR 0 numeric_source_location_not_verified;small_denominator Abstract, Results
R084 · Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. PMID:34000246 · The Lancet. Oncology · 2021 · 6 flagged records
Identifiers (bibliographic snapshot): PMID:34000246 · DOI:10.1016/S1470-2045(21)00126-1
Citation · Publisher / DOI
Cancer codes: BCC
Flags: numeric_source_location_not_verified
Show 6 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response BCC/PD-1 BCC ORR 31.0 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response BCC/PD-1 BCC ORR 31.0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-52dbc5d599-01 BCC ORR 31 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-9394b751d8-01 BCC DCR 80 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-6eab5da93b-01 BCC DURABLE DISEASE CONTROL 60 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-d465ee2e25-01 BCC PFS 19 numeric_source_location_not_verified Abstract, Findings
R096 · Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. PMID:36808285 · Neuro-oncology · 2023 · 6 flagged records
Identifiers (bibliographic snapshot): PMID:36808285 · DOI:10.1093/neuonc/noad031 · PMCID:PMC10398811
Citation · Publisher / DOI · PMC full text
Cancer codes: DIPG; EPN; MBL
Flags: numeric_source_location_not_verified
Show 6 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-9459107c19-01 DIPG ORR 0 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-d318c83a29-01 EPN PFS_RATE 27.3 numeric_source_location_not_verified Results > No Survival Benefit Was Observed Across Cohorts cancer-ici-response-estimates ICI-0ec5911eda-01 EPN ORR 0 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-ab59b6106e-01 EPN PFS_RATE 11.4 numeric_source_location_not_verified Results > No Survival Benefit Was Observed Across Cohorts cancer-ici-response-estimates ICI-d9f97a062f-01 MBL ORR 0 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-9374924e16-01 MBL ORR 0 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results
R002 · Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. DOI:10.1016/j.annonc.2023.10.123 · Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:38072158 · DOI:10.1016/j.annonc.2023.10.123
Citation
Cancer codes: BCC
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-19956d182d-01 BCC ORR 22 numeric_source_location_not_verified cancer-ici-response-estimates ICI-4398a82d1e-01 BCC CRR 3.7 numeric_source_location_not_verified cancer-ici-response-estimates ICI-143d70f5e9-01 BCC PR 18.5 numeric_source_location_not_verified cancer-ici-response-estimates ICI-cb7e1bb636-01 BCC PFS 10 numeric_source_location_not_verified cancer-ici-response-estimates ICI-ed94d6f902-01 BCC OS 50 numeric_source_location_not_verified
R012 · Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. DOI:10.1182/blood.2019004753 · Blood · 2021 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:32870269 · DOI:10.1182/blood.2019004753 · PMCID:PMC7869188
Citation · PMC full text
Cancer codes: FL
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-7b62042b23-01 FL CRR 1 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-ad7e64190e-01 FL PRR 3 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-abaced8733-01 FL OS_RATE 78 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-b6231dd107-01 FL OS_RATE 88 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-b18146c252-01 FL ORR 11 numeric_source_location_not_verified Abstract
R015 · A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). DOI:10.1200/JCO.2020.38.15_suppl.6513 · Journal of Clinical Oncology · 2020 · 5 flagged records
Identifiers (bibliographic snapshot): DOI:10.1200/jco.2020.38.15_suppl.6513
Citation · Publisher / DOI
Cancer codes: ATC
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response ATC/PD-1+CTLA-4 ATC ORR 30.0 numeric_source_location_not_verified cancer-apd1-response ATC/PD-1+CTLA-4 ATC ORR 30.0 numeric_source_location_not_verified cancer-ici-response-estimates ICI-deeb11dc2d-01 ATC ORR 30 numeric_source_location_not_verified cancer-ici-response-estimates ICI-cb72c7e2fd-01 ATC CBR 50 numeric_source_location_not_verified cancer-ici-response-estimates ICI-966148cfb1-01 ATC ORR 9.4 excluded_from_pooling;numeric_source_location_not_verified
R033 · Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. PMID:28223062 · The Lancet. Oncology · 2017 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:28223062 · DOI:10.1016/S1470-2045(17)30104-3 · PMCID:PMC5809128
Citation · Publisher / DOI · PMC full text
Cancer codes: ANSC
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response ANSC/PD-1 ANSC ORR 24.0 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response ANSC/PD-1 ANSC ORR 24.0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-8624416b0e-01 ANSC ORR 24 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-8cd76d5098-01 ANSC CRR 5.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-943547eb15-01 ANSC PR 18.9 numeric_source_location_not_verified Abstract, Findings
R040 · Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. PMID:29045540 · Annals of oncology : official journal of the European Society for Medical Oncology · 2018 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:29045540 · DOI:10.1093/annonc/mdx680
Citation · Publisher / DOI
Cancer codes: TGCT
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response TGCT/PD-1 TGCT ORR 0.0 numeric_source_location_not_verified Abstract, Results cancer-apd1-response TGCT/PD-1 TGCT ORR 0.0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-e37537fa7c-01 TGCT ORR 0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-2fe21eab0e-01 TGCT CRR 0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-49ee9f3ea2-01 TGCT DCR 16.7 numeric_source_location_not_verified Abstract, Results
R045 · Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. PMID:29562145 · The New England journal of medicine · 2018 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:29562145 · DOI:10.1056/NEJMoa1712126 · PMCID:PMC5972549
Citation · Publisher / DOI · PMC full text
Cancer codes: KIRC
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response KIRC/PD-1+CTLA-4 KIRC ORR 41.6 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-dd6e17da69-01 KIRC ORR 41.6 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-a400b2be5c-01 KIRC CRR 9.4 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-558467b418-01 KIRC ORR 26.5 excluded_from_pooling;numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-e02a6a2af9-01 KIRC ORR 39 numeric_source_location_not_verified Abstract, RESULTS
R053 · Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. PMID:30242306 · JAMA oncology · 2019 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:30242306 · DOI:10.1001/jamaoncol.2018.4224 · PMCID:PMC6439773
Citation · Publisher / DOI · PMC full text
Cancer codes: BRCA_TNBC
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response BRCA_TNBC/PD-L1 BRCA_TNBC ORR 10.0 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-3792c43928-01 BRCA_TNBC ORR 10 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-7353d7284b-01 BRCA_TNBC ORR 24 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-6bbe217c59-01 BRCA_TNBC ORR 6 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-dd8d58275c-01 BRCA_TNBC ORR 12 numeric_source_location_not_verified Abstract, Findings
R091 · Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. PMID:35289329 · Nature communications · 2022 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:35289329 · DOI:10.1038/s41467-022-29052-7 · PMCID:PMC8921328
Citation · Publisher / DOI · PMC full text
Cancer codes: MENINGIOMA
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response MENINGIOMA/PD-1 MENINGIOMA ORR 0.0 numeric_source_location_not_verified Abstract cancer-apd1-response MENINGIOMA/PD-1 MENINGIOMA ORR 0.0 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-7502d759c8-01 MENINGIOMA ORR 0 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-52e16b7ccb-01 MENINGIOMA PFS_RATE 48 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-6391ac3bad-01 MENINGIOMA PFS_RATE 50 numeric_source_location_not_verified Abstract
R099 · Atezolizumab for Advanced Alveolar Soft Part Sarcoma. PMID:37672694 · The New England journal of medicine · 2023 · 5 flagged records
Identifiers (bibliographic snapshot): PMID:37672694 · DOI:10.1056/NEJMoa2303383 · PMCID:PMC10729808
Citation · Publisher / DOI · PMC full text
Cancer codes: SARC_ASPS
Flags: numeric_source_location_not_verified
Show 5 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SARC_ASPS/PD-L1 SARC_ASPS ORR 37.0 numeric_source_location_not_verified Abstract, RESULTS cancer-apd1-response SARC_ASPS/PD-L1 SARC_ASPS ORR 37.0 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-68f695eab6-01 SARC_ASPS ORR 37 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-ac6660f176-01 SARC_ASPS CRR 1.9 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-0c6031d882-01 SARC_ASPS TUMOR_SHRINKAGE -66.2 numeric_source_location_not_verified
R010 · A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors DOI:10.1158/1078-0432.CCR-19-3356 · Clinical Cancer Research · 2020 · 4 flagged records
Identifiers (bibliographic snapshot): DOI:10.1158/1078-0432.ccr-19-3356
Citation · Existing source document
Cancer codes: NEC_LUNG_LARGECELL
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-60d4f8bbbc-01 NEC_LUNG_LARGECELL CRR 3 numeric_source_location_not_verified cancer-ici-response-estimates ICI-b5215aa0e8-01 NEC_LUNG_LARGECELL PFS 4 numeric_source_location_not_verified RESULTS > Outcomes cancer-ici-response-estimates ICI-738e4fb409-01 NEC_LUNG_LARGECELL OS 11 numeric_source_location_not_verified RESULTS > Outcomes cancer-ici-response-estimates ICI-0bf25b2b25-01 NEC_LUNG_LARGECELL PFS_RATE 31 numeric_source_location_not_verified RESULTS > Outcomes
R011 · Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. DOI:10.1182/blood-2017-02-765685 · Blood · 2017 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:28424162 · DOI:10.1182/blood-2017-02-765685 · PMCID:PMC5492091
Citation · PMC full text
Cancer codes: CLL
Flags: numeric_source_location_not_verified; small_denominator
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response CLL/PD-1 CLL ORR 0.0 numeric_source_location_not_verified Abstract cancer-apd1-response CLL/PD-1 CLL ORR 0.0 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-4f6402b639-01 CLL ORR 0 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-c319898ee7-01 CLL ORR 44.4 numeric_source_location_not_verified;small_denominator Abstract
R032 · Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. PMID:28131785 · The Lancet. Oncology · 2017 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:28131785 · DOI:10.1016/S1470-2045(17)30065-7
Citation · Publisher / DOI
Cancer codes: BLCA
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-22d7ca6935-01 BLCA ORR 19.6 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-1c4c4cfa84-01 BLCA ORR 28.4 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-bde6ff938a-01 BLCA ORR 16.1 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-c4d53723ca-01 BLCA PFS 2 numeric_source_location_not_verified Abstract, Findings
R037 · Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. PMID:28889792 · The New England journal of medicine · 2017 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:28889792 · DOI:10.1056/NEJMoa1709684 · PMCID:PMC5706778
Citation · Publisher / DOI · PMC full text
Cancer codes: SKCM
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SKCM/PD-1 SKCM ORR 43.7 numeric_source_location_not_verified Abstract, RESULTS cancer-apd1-response SKCM/PD-1 SKCM ORR 43.7 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-c45f7ddf79-01 SKCM ORR 43.7 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-20b555f216-01 SKCM ORR 57.6 numeric_source_location_not_verified Abstract, RESULTS
R042 · Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. PMID:29395863 · The Lancet. Oncology · 2018 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:29395863 · DOI:10.1016/S1470-2045(18)30062-7 · PMCID:PMC10683856
Citation · Publisher / DOI · PMC full text
Cancer codes: THYMCA
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response THYMCA/PD-1 THYMCA ORR 22.5 numeric_source_location_not_verified Abstract, Findings cancer-apd1-response THYMCA/PD-1 THYMCA ORR 22.5 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-1db7f7a7ad-01 THYMCA ORR 22.5 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-d27552d68f-01 THYMCA SD 52.5 numeric_source_location_not_verified Abstract, Findings
R047 · STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. PMID:29773717 · Cancer discovery · 2018 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:29773717 · DOI:10.1158/2159-8290.CD-18-0099 · PMCID:PMC6030433
Citation · Publisher / DOI · PMC full text
Cancer codes: LUAD_STK11
Flags: numeric_source_location_not_verified; response_denominator_missing; small_denominator
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-b3d0d4438b-01 LUAD_STK11 ORR 8 excluded_from_pooling;numeric_source_location_not_verified;response_denominator_missing cancer-ici-response-estimates ICI-40ee4f78ab-01 LUAD_STK11 ORR 8 excluded_from_pooling;numeric_source_location_not_verified;response_denominator_missing cancer-ici-response-estimates ICI-40ee4f78ab-02 LUAD_STK11 ORR 8 excluded_from_pooling;numeric_source_location_not_verified;response_denominator_missing cancer-ici-response-estimates ICI-1c401c554d-01 LUAD_STK11 ORR 0 excluded_from_pooling;small_denominator Figure 1B; Results, Co-mutations in STK11/LKB1
R061 · Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. PMID:30937889 · British journal of haematology · 2019 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:30937889 · DOI:10.1111/bjh.15888
Citation · Publisher / DOI
Cancer codes: MM
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response MM/PD-1 MM ORR 0.0 numeric_source_location_not_verified cancer-apd1-response MM/PD-1 MM ORR 0.0 numeric_source_location_not_verified cancer-ici-response-estimates ICI-94980ac18f-01 MM ORR 0 numeric_source_location_not_verified cancer-ici-response-estimates ICI-a45ca3ed48-01 MM DCR 56.7 numeric_source_location_not_verified
R066 · Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. PMID:31562796 · The New England journal of medicine · 2019 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:31562796 · DOI:10.1056/NEJMoa1910231
Citation · Publisher / DOI
Cancer codes: LUAD
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response LUAD/PD-1+CTLA-4 LUAD ORR 35.9 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-629c395ded-01 LUAD ORR 35.9 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-baed09d614-01 LUAD CRR 5.8 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-f7bf901d27-01 LUAD PFS 5.1 numeric_source_location_not_verified Abstract, Results
R089 · Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. PMID:35108470 · The New England journal of medicine · 2022 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:35108470 · DOI:10.1056/NEJMoa2111380
Citation · Publisher / DOI
Cancer codes: ESCA
Flags: numeric_source_location_not_verified
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-b6aab72384-01 ESCA DOR 11.1 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-1a821e877e-01 ESCA ORR 35 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-7adb9b1ccb-01 ESCA ORR 47 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-30fdf982ae-01 ESCA ORR 53 numeric_source_location_not_verified Abstract, Results
R094 · Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. PMID:35777186 · European journal of cancer (Oxford, England : 1990) · 2022 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:35777186 · DOI:10.1016/j.ejca.2022.05.007
Citation · Publisher / DOI
Cancer codes: SGC
Flags: numeric_source_location_not_verified; response_denominator_missing; small_denominator
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-9bfcbfbb51-01 SGC CRR 0.9 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-071eb5e3c9-01 SGC ORR 10.7 response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-ace3bf531f-01 SGC ORR 2.6 response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-7c006ed354-01 SGC DOR small_denominator Abstract, Results
R102 · A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. PMID:39343511 · Journal for immunotherapy of cancer · 2024 · 4 flagged records
Identifiers (bibliographic snapshot): PMID:39343511 · DOI:10.1136/jitc-2024-009472 · PMCID:PMC11440204
Citation · Publisher / DOI · PMC full text
Cancer codes: SARC_GIST
Flags: numeric_source_location_not_verified; small_denominator
Show 4 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SARC_GIST/PD-1 SARC_GIST ORR 0.0 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-apd1-response SARC_GIST/PD-1 SARC_GIST ORR 0.0 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-c5a846763f-01 SARC_GIST ORR 0 numeric_source_location_not_verified;small_denominator Abstract, Results cancer-ici-response-estimates ICI-3ce1bd36b9-01 SARC_GIST ORR 0 numeric_source_location_not_verified;small_denominator Abstract, Results
R014 · KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC). DOI:10.1200/JCO.2019.37.15_suppl.4569 · Journal of Clinical Oncology · 2019 · 3 flagged records
Identifiers (bibliographic snapshot): DOI:10.1200/jco.2019.37.15_suppl.4569
Citation · Publisher / DOI
Cancer codes: RCC_NCC; RCC_NCC_UNCLASSIFIED
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-e1696a6eee-01 RCC_NCC ORR 24.8 numeric_source_location_not_verified cancer-ici-response-estimates ICI-ba2c15eea4-01 RCC_NCC CRR 4.8 numeric_source_location_not_verified cancer-ici-response-estimates ICI-3c0861434d-01 RCC_NCC_UNCLASSIFIED ORR 34.6 numeric_source_location_not_verified
R026 · Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. PMID:26412456 · The New England journal of medicine · 2015 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:26412456 · DOI:10.1056/NEJMoa1507643 · PMCID:PMC5705936
Citation · Publisher / DOI · PMC full text
Cancer codes: LUAD
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-21dbb61b2b-01 LUAD ORR 31 numeric_source_location_not_verified;response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-9abbc81fd4-01 LUAD ORR 36 numeric_source_location_not_verified;response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-d7be178df9-01 LUAD ORR 9 numeric_source_location_not_verified;response_denominator_missing Abstract, Results
R030 · Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. PMID:27592805 · The Lancet. Oncology · 2016 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:27592805 · DOI:10.1016/S1470-2045(16)30364-3 · PMCID:PMC5587154
Citation · Publisher / DOI · PMC full text
Cancer codes: NEC_MERKEL
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response NEC_MERKEL/PD-L1 NEC_MERKEL ORR 31.8 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-ccdfa8d759-01 NEC_MERKEL ORR 31.8 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-99299f59bb-01 NEC_MERKEL CRR 9.1 numeric_source_location_not_verified Abstract, Findings
R054 · Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. PMID:30383184 · JAMA oncology · 2019 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:30383184 · DOI:10.1001/jamaoncol.2018.4628 · PMCID:PMC6439564
Citation · Publisher / DOI · PMC full text
Cancer codes: HNSC
Flags: response_denominator_missing
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-ae503046aa-01 HNSC ORR 9.2 response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-4614dbd717-01 HNSC ORR 7.8 response_denominator_missing Abstract, Results cancer-ici-response-estimates ICI-c9a3ab079d-01 HNSC ORR 1.6 response_denominator_missing Abstract, Results
R057 · T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. PMID:30557521 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:30557521 · DOI:10.1200/JCO.2018.78.2276
Citation · Publisher / DOI
Cancer codes: PAAD
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response PAAD/PD-1 PAAD ORR 0.0 numeric_source_location_not_verified Abstract, Results cancer-apd1-response PAAD/PD-1 PAAD ORR 0.0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-f39b833d2e-01 PAAD ORR 0 numeric_source_location_not_verified Abstract, Results
R060 · A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. PMID:30664989 · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:30664989 · DOI:10.1016/j.jtho.2019.01.008
Citation · Publisher / DOI
Cancer codes: SCLC
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response SCLC/PD-L1 SCLC ORR 2.3 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-90f14ccfd4-01 SCLC ORR 2.3 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-3b629d1cb9-01 SCLC ORR 10 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results
R070 · Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. PMID:31682550 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:31682550 · DOI:10.1200/JCO.19.02105 · PMCID:PMC8184060
Citation · Publisher / DOI · PMC full text
Cancer codes: PAAD
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-75483f30c4-01 PAAD ORR 18.2 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-f45b1f0a1b-01 PAAD PFS 2 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-f36557e601-01 PAAD DOR 13.4 numeric_source_location_not_verified
R085 · Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). PMID:34380663 · Journal for immunotherapy of cancer · 2021 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:34380663 · DOI:10.1136/jitc-2021-002990 · PMCID:PMC8330584
Citation · Publisher / DOI · PMC full text
Cancer codes: SARC_ANGIO
Flags: numeric_source_location_not_verified; small_denominator
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-d4b9ddceed-01 SARC_ANGIO CRR 6.25 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-ca26aa02c1-01 SARC_ANGIO DOR small_denominator Abstract, Results cancer-ici-response-estimates ICI-31cd333339-01 SARC_ANGIO ORR 60 small_denominator Results > Outcomes
R086 · Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung. PMID:34590004 · JTO clinical and research reports · 2021 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:34590004 · DOI:10.1016/j.jtocrr.2020.100129 · PMCID:PMC8474479
Citation · Publisher / DOI · PMC full text
Cancer codes: NEC_LUNG_LARGECELL
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response NEC_LUNG_LARGECELL/PD-1 NEC_LUNG_LARGECELL ORR 29.4 numeric_source_location_not_verified Results > Efficacy of Nivolumab cancer-apd1-response NEC_LUNG_LARGECELL/PD-1 NEC_LUNG_LARGECELL ORR 29.4 numeric_source_location_not_verified Results > Efficacy of Nivolumab cancer-ici-response-estimates ICI-0415d548a7-01 NEC_LUNG_LARGECELL ORR 29.4 numeric_source_location_not_verified Results > Efficacy of Nivolumab
R088 · Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. PMID:34990208 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 3 flagged records
Identifiers (bibliographic snapshot): PMID:34990208 · DOI:10.1200/JCO.21.01874 · PMCID:PMC8887941
Citation · Publisher / DOI · PMC full text
Cancer codes: UCEC_MSI
Flags: numeric_source_location_not_verified
Show 3 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-666d42d93f-01 UCEC_MSI CRR 14 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-74214de11c-01 UCEC_MSI PRR 34 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-c08a7eeed5-01 UCEC_MSI MEDIAN_FOLLOW_UP 42.6 numeric_source_location_not_verified
R006 · Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. DOI:10.1038/s41416-020-0775-0 · British journal of cancer · 2020 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:32152503 · DOI:10.1038/s41416-020-0775-0 · PMCID:PMC7188798
Citation · PMC full text
Cancer codes: NEN_EXTRAPULMONARY_HG
Flags: numeric_source_location_not_verified; small_denominator
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-460c94526d-01 NEN_EXTRAPULMONARY_HG CRR 0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-c01eb65fd7-01 NEN_EXTRAPULMONARY_HG DOR 13 numeric_source_location_not_verified;small_denominator Abstract, Results
R009 · Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. DOI:10.1080/10428194.2022.2034155 · Leukemia & lymphoma · 2022 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:35244520 · DOI:10.1080/10428194.2022.2034155
Citation
Cancer codes: MDS
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-13b1a410d0-01 MDS OS 6 numeric_source_location_not_verified cancer-ici-response-estimates ICI-ba05b51ac5-01 MDS OS_RATE 17 numeric_source_location_not_verified
R031 · Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. PMID:27718847 · The New England journal of medicine · 2016 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:27718847 · DOI:10.1056/NEJMoa1606774
Citation · Publisher / DOI
Cancer codes: LUAD; LUSC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-0f54d83fe4-01 LUAD ORR 44.8 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-fef3211a5c-01 LUSC ORR 44.8 numeric_source_location_not_verified Abstract, Results
R049 · Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. PMID:29867230 · Nature medicine · 2018 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:29867230 · DOI:10.1038/s41591-018-0053-3 · PMCID:PMC6721896
Citation · Publisher / DOI · PMC full text
Cancer codes: KIRC
Flags: response_denominator_missing
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-e6fa7070be-01 KIRC ORR 28 response_denominator_missing Results > Efficacy. cancer-ici-response-estimates ICI-36e5ed46b2-01 KIRC ORR 46 response_denominator_missing Results > Efficacy.
R062 · Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. PMID:30943124 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:30943124 · DOI:10.1200/JCO.18.01265
Citation · Publisher / DOI
Cancer codes: CESC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-ddd8d6f347-01 CESC CRR 3.1 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-2e11ae750c-01 CESC DCR 30.6 numeric_source_location_not_verified Abstract, Results
R065 · Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. PMID:31532724 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:31532724 · DOI:10.1200/JCO.19.01056 · PMCID:PMC6943974
Citation · Publisher / DOI · PMC full text
Cancer codes: CTCL
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-8f71cb2eac-01 CTCL CRR 8.3 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-c32679e1c3-01 CTCL PR_RATE 29.2 numeric_source_location_not_verified Abstract, RESULTS
R071 · Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. PMID:32359091 · International journal of cancer · 2020 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:32359091 · DOI:10.1002/ijc.33013
Citation · Publisher / DOI
Cancer codes: BTC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-784ad2abd2-01 BTC PFS 1.8 numeric_source_location_not_verified Abstract cancer-ici-response-estimates ICI-45d73edf58-01 BTC OS 5.7 numeric_source_location_not_verified Abstract
R072 · Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. PMID:32552471 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:32552471 · DOI:10.1200/JCO.19.01213
Citation · Publisher / DOI
Cancer codes: BLCA
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-278a4de643-01 BLCA CRR 8.9 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-def378bec0-01 BLCA ORR 47.3 response_denominator_missing Abstract, Results
R073 · Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). PMID:32673170 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:32673170 · DOI:10.1200/JCO.19.03054 · PMCID:PMC7460151
Citation · Publisher / DOI · PMC full text
Cancer codes: cSCC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-8d0d9e4e21-01 cSCC CRR 3.8 numeric_source_location_not_verified Abstract, RESULTS cancer-ici-response-estimates ICI-3b85b565b0-01 cSCC PRR 30.5 numeric_source_location_not_verified Abstract, RESULTS
R074 · Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. PMID:32997907 · The New England journal of medicine · 2020 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:32997907 · DOI:10.1056/NEJMoa1917346
Citation · Publisher / DOI
Cancer codes: NSCLC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response NSCLC/PD-L1 NSCLC ORR 38.3 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-e0081e5893-01 NSCLC ORR 38.3 numeric_source_location_not_verified Abstract, Results
R090 · Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. PMID:35114169 · The lancet. Gastroenterology & hepatology · 2022 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:35114169 · DOI:10.1016/S2468-1253(21)00382-4 · PMCID:PMC12012850
Citation · Publisher / DOI · PMC full text
Cancer codes: ANSC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-cfb30dbca5-01 ANSC ORR 11 numeric_source_location_not_verified Abstract, Findings cancer-ici-response-estimates ICI-ccc536e5e5-01 ANSC ORR 15 numeric_source_location_not_verified Abstract, Findings
R093 · Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. PMID:35611499 · Cancer medicine · 2022 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:35611499 · DOI:10.1002/cam4.4593 · PMCID:PMC9249982
Citation · Publisher / DOI · PMC full text
Cancer codes: BTC
Flags: numeric_source_location_not_verified
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-1a2bac306d-01 BTC CRR 0 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-37635ad717-01 BTC CRR 0 numeric_source_location_not_verified Abstract, Results
R100 · A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). PMID:38858106 · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024 · 2 flagged records
Identifiers (bibliographic snapshot): PMID:38858106 · DOI:10.1136/ijgc-2024-005588
Citation · Publisher / DOI
Cancer codes: CESC
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 2 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-13c6b42ce9-01 CESC ORR 19 numeric_source_location_not_verified Abstract, Results cancer-ici-response-estimates ICI-2814c8c5da-01 CESC ORR 20.7 numeric_source_location_not_verified;response_denominator_missing
R016 · Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. DOI:10.3390/cancers12082307 · Cancers · 2020 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:32824391 · DOI:10.3390/cancers12082307 · PMCID:PMC7465458
Citation · PMC full text
Cancer codes: PCPG
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-aa8e0e890b-01 PCPG PFS 5.7 numeric_source_location_not_verified Abstract
R023 · Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. PMID:26027431 · The New England journal of medicine · 2015 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:26027431 · DOI:10.1056/NEJMoa1504030 · PMCID:PMC5698905
Citation · Publisher / DOI · PMC full text
Cancer codes: SKCM
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-8fd36e30fa-01 SKCM ORR 19 numeric_source_location_not_verified Abstract, Results
R024 · PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. PMID:26028255 · The New England journal of medicine · 2015 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:26028255 · DOI:10.1056/NEJMoa1500596 · PMCID:PMC4481136
Citation · Publisher / DOI · PMC full text
Cancer codes: CRC_MSI
Flags: small_denominator
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-4ab1cc05e0-01 CRC_MSI PFS_RATE 78 small_denominator RESULTS > PRIMARY END POINT
R027 · Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. PMID:27159395 · The Journal of clinical investigation · 2016 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:27159395 · DOI:10.1172/JCI84940 · PMCID:PMC4887167
Citation · Publisher / DOI · PMC full text · Existing source document
Cancer codes: UCEC_POLE
Flags: small_denominator
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-64a41d348a-01 UCEC_POLE PR_COUNT 1 small_denominator Results and Discussion, partial response at 8 weeks
R029 · Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. PMID:27533448 · Cancer · 2016 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:27533448 · DOI:10.1002/cncr.30258 · PMCID:PMC5767160
Citation · Publisher / DOI · PMC full text
Cancer codes: UVM
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-8e49d3b5f6-01 UVM DURABLE DISEASE CONTROL 9 numeric_source_location_not_verified Abstract, RESULTS
R041 · Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. PMID:29217288 · The Lancet. Oncology · 2018 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:29217288 · DOI:10.1016/S1470-2045(17)30900-2 · PMCID:PMC7984727
Citation · Publisher / DOI · PMC full text
Cancer codes: BLCA
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-9e11d8b7bd-01 BLCA ORR 17 numeric_source_location_not_verified Abstract, Findings
R046 · Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. PMID:29584546 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:29584546 · DOI:10.1200/JCO.2017.76.0793 · PMCID:PMC6075855
Citation · Publisher / DOI · PMC full text
Cancer codes: HL
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-2588285332-01 HL IRORR 71 numeric_source_location_not_verified Abstract, Results
R048 · PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. PMID:29863979 · The New England journal of medicine · 2018 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:29863979 · DOI:10.1056/NEJMoa1805131
Citation · Publisher / DOI
Cancer codes: cSCC
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-897a51cb7a-01 cSCC ORR 47 numeric_source_location_not_verified Abstract, Results
R051 · Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. PMID:29906252 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:29906252 · DOI:10.1200/JCO.2017.77.3184
Citation · Publisher / DOI
Cancer codes: THYMCA
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-74053911de-01 THYMCA ORR 19.2 numeric_source_location_not_verified Abstract, Results
R055 · Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. PMID:30475947 · Annals of oncology : official journal of the European Society for Medical Oncology · 2019 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:30475947 · DOI:10.1093/annonc/mdy518
Citation · Publisher / DOI
Cancer codes: BRCA_TNBC
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-9fc9ca17f2-01 BRCA_TNBC CRR 4.8 numeric_source_location_not_verified Abstract, Results
R056 · Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. PMID:30475950 · Annals of oncology : official journal of the European Society for Medical Oncology · 2019 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:30475950 · DOI:10.1093/annonc/mdy517
Citation · Publisher / DOI
Cancer codes: BRCA_TNBC
Flags: response_denominator_missing
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-00a12fc413-01 BRCA_TNBC ORR 5.7 response_denominator_missing Abstract, Results
R058 · Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. PMID:30605211 · JAMA oncology · 2019 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:30605211 · DOI:10.1001/jamaoncol.2018.5428 · PMCID:PMC6439847
Citation · Publisher / DOI · PMC full text
Cancer codes: MESO
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-bc313ba925-01 MESO DOR 15.2 numeric_source_location_not_verified Abstract, Findings
R075 · Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. PMID:33001135 · JAMA oncology · 2020 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33001135 · DOI:10.1001/jamaoncol.2020.4564 · PMCID:PMC7530824
Citation · Publisher / DOI · PMC full text
Cancer codes: LIHC
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-ee55df807c-01 LIHC DCR 64 numeric_source_location_not_verified Abstract, Findings
R076 · Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. PMID:33026938 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33026938 · DOI:10.1200/JCO.20.01888
Citation · Publisher / DOI
Cancer codes: ESCA
Flags: numeric_source_location_not_verified; response_denominator_missing
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-a4abe5b031-01 ESCA ORR 16.7 numeric_source_location_not_verified;response_denominator_missing Abstract, Results
R078 · Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. PMID:33264544 · The New England journal of medicine · 2020 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33264544 · DOI:10.1056/NEJMoa2017699
Citation · Publisher / DOI
Cancer codes: CRC_MSI
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-072ab82577-01 CRC_MSI ORR 33.1 excluded_from_pooling;numeric_source_location_not_verified Abstract, Results
R079 · Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). PMID:33417511 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33417511 · DOI:10.1200/JCO.20.00550
Citation · Publisher / DOI
Cancer codes: UVM
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-ed31cd419b-01 UVM ORR 11.5 numeric_source_location_not_verified Abstract, Results
R081 · Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. PMID:33529058 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33529058 · DOI:10.1200/JCO.20.02365 · PMCID:PMC8078262
Citation · Publisher / DOI · PMC full text
Cancer codes: RCC_NCC
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-5b931e41ff-01 RCC_NCC CRR 6.7 numeric_source_location_not_verified Abstract, RESULTS
R083 · A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. PMID:33882143 · Cancer · 2021 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:33882143 · DOI:10.1002/cncr.33591 · PMCID:PMC8606104
Citation · Publisher / DOI · PMC full text
Cancer codes: NEC_LUNG_LARGECELL
Flags: response_denominator_missing
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-e715592be4-01 NEC_LUNG_LARGECELL ORR 26 excluded_from_pooling;response_denominator_missing Abstract; Results, Patient Characteristics
R087 · Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. PMID:34818112 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:34818112 · DOI:10.1200/JCO.21.02229 · PMCID:PMC8718224
Citation · Publisher / DOI · PMC full text
Cancer codes: SKCM
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-a1bc8eafa7-01 SKCM ORR 58 numeric_source_location_not_verified Abstract, RESULTS
R092 · Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. PMID:35361487 · Gynecologic oncology · 2022 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:35361487 · DOI:10.1016/j.ygyno.2022.01.029
Citation · Publisher / DOI
Cancer codes: VSCC
Flags: small_denominator
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-15d1787eb3-01 VSCC ORR 28.6 small_denominator Abstract, Results
R097 · Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. PMID:37130017 · Blood · 2023 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:37130017 · DOI:10.1182/blood.2022019340 · PMCID:PMC10651864
Citation · Publisher / DOI · PMC full text
Cancer codes: PMBCL
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-80526a3d45-01 PMBCL PFS_RATE 33 numeric_source_location_not_verified Abstract
R103 · Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. PMID:39356983 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:39356983 · DOI:10.1200/JCO.24.00640 · PMCID:PMC11779594
Citation · Publisher / DOI · PMC full text
Cancer codes: SARC_KS
Flags: small_denominator
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-08a3707108-01 SARC_KS ORR 87.5 small_denominator Abstract, RESULTS:
R104 · Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. PMID:39631622 · Annals of oncology : official journal of the European Society for Medical Oncology · 2025 · 1 flagged records
Identifiers (bibliographic snapshot): PMID:39631622 · DOI:10.1016/j.annonc.2024.11.012
Citation · Publisher / DOI
Cancer codes: CRC_MSI
Flags: numeric_source_location_not_verified
Show 1 mapped records and existing locators Dataset Row key Cancer Metric Value Flags Existing locator cancer-ici-response-estimates ICI-c51444aea4-01 CRC_MSI ORR 45.8 numeric_source_location_not_verified Abstract, Results
Records without a direct citation ICI-dfd5824394-01 · COAD · prevalence-weighted blend of CRC_MSI source-scope ORR (43.8%) + COAD_MSS (0%) at dMMR prevalence ~13%; not a single-trial value; 43.8*0.13 = 5.7% ~ 5% ICI-f37d406872-01 · READ · prevalence-weighted blend of CRC_MSI source-scope ORR (43.8%) + READ_MSS (0%) at rectal dMMR prevalence ~4.5% (range 3-5%); not a single-trial value; 0.045*43.8 = ~2% ICI-506b32f2a7-01 · UCEC · prevalence-weighted blend of UCEC_MSI (48%) + UCEC_CNL/CNH pMMR (7%) at dMMR prevalence ~20%; not a single-trial value; KEYNOTE-158 both cohorts; 0.20*48 + 0.80*7 = 15.2%; advanced-EC dMMR prevalence ~20%